STAT+: Pharmalittle: We’re reading about a broader $35 insulin cap, a former FDA cancer drug chief, and more

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and the like has returned with a vengeance. You knew this would happen, yes? To cope, we are relying, as always, on cups of stimulation. Our choice today is strawberry creme. Please feel free to join us. Meanwhile, here is the latest menu of tidbits for you to peruse. We hope that your day is absolutely smashing and that you conquer the world. And of course, do keep in touch. We treasure your feedback and insights. … The head of the pharmaceutical industry trade group in Switzerland said the U.S. could open a trade investigation similar to the one initiated last week ​against Germany, Reuters writes. Washington has launched so-called Section 301 investigation into suspected unfair trade practices against dozens of countries. It initiated the probe against Germany after Berlin unveiled plans in April ‌for ​a wide-ranging overhaul of its ⁠statutory health care system, including ⁠plans to lower spending on pharmaceutical products. The investigation could result in the U.S. taking tariff-related action against German imports. Switzerland is also currently reviewing measures ⁠aimed at reducing mandatory health care ⁠prices, which could see drug prices lowered, ​something the industry has criticized. The search for affordability wins to boast about on the campaign trail is leading U.S. senators back to capping the cost of insulin at $35 in the private insurance market and for the uninsured, Bloomberg Government News tell us. The proposal is modeled on a similar measure Democrats included in their 2022 tax-and-health care law designed to curb costs for the diabetes drug in the Medicare health insurance program for seniors. This time, the private-market insulin cap is being pushed by Sen. Susan Collins (R-Maine), who is